We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.42B
AUM Growth
-$48.5M
Cap. Flow
+$49.9M
Cap. Flow %
3.5%
Top 10 Hldgs %
29.29%
Holding
97
New
3
Increased
35
Reduced
20
Closed
5

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$33.3M
2
PFE icon
Pfizer
PFE
+$22.2M
3
BIIB icon
Biogen
BIIB
+$19.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.4M
5
MCK icon
McKesson
MCK
+$14M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.6M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$20.4M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.94M
5
PHR icon
Phreesia
PHR
+$9.11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Industrials 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
51
DELISTED
Revance Therapeutics, Inc.
RVNC
$8.91M 0.63%
320,000
+50,000
+19% +$1.43M
AERI
52
DELISTED
Aerie Pharmaceuticals
AERI
$8.55M 0.6%
750,000
– –
ONEM
53
DELISTED
1Life Healthcare
ONEM
$8.51M 0.6%
420,000
+90,000
+27% +$2.31M
SILK
54
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$8.03M 0.56%
146,000
– –
IOVA icon
55
Iovance Biotherapeutics
IOVA
$2.9B
$7.89M 0.55%
320,000
+20,000
+7% +$471K
HRMY icon
56
Harmony Biosciences
HRMY
$2.27B
$7.85M 0.55%
204,876
+104,876
+105% +$3.38M
PHR icon
57
Phreesia
PHR
$769M
$7.62M 0.53%
123,465
-136,535
-53% -$9.11M
ESPR
58
DELISTED
Esperion Therapeutics
ESPR
$7.5M 0.53%
622,267
+50,000
+9% +$728K
BMY icon
59
Bristol-Myers Squibb
BMY
$132B
$7.4M 0.52%
125,000
– –
GKOS icon
60
Glaukos
GKOS
$10.7B
$7.23M 0.51%
150,000
+115,000
+329% +$6.38M
SWAV
61
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$7M 0.49%
34,000
+10
+0% +$1.96K
NVCR icon
62
NovoCure
NVCR
$2.02B
$6.97M 0.49%
60,000
-60,000
-50% -$9.07M
IMGN
63
DELISTED
Immunogen Inc
IMGN
$6.91M 0.49%
1,218,850
– –
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.89M 0.48%
765,000
– –
ALKS icon
65
Alkermes
ALKS
$8.29B
$6.48M 0.45%
210,000
-99,354
-32% -$2.81M
PHAT icon
66
Phathom Pharmaceuticals
PHAT
$693M
$5.98M 0.42%
186,210
– –
MGTX icon
67
MeiraGTx Holdings
MGTX
$1.21B
$5.93M 0.42%
450,000
– –
ISEE
68
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.68M 0.4%
+350,000
New +$3.81M
PRVA icon
69
Privia Health
PRVA
$2.86B
$5.65M 0.4%
+240,000
New +$8.38M
MYOV
70
DELISTED
Myovant Sciences Ltd.
MYOV
$5.61M 0.39%
250,000
– –
VRAY
71
DELISTED
ViewRay, Inc.
VRAY
$5.59M 0.39%
775,000
– –
RIGL icon
72
Rigel Pharmaceuticals
RIGL
$778M
$5.52M 0.39%
152,000
– –
RDUS
73
DELISTED
Radius Health, Inc.
RDUS
$5.34M 0.37%
430,000
– –
FLNA
74
Filana Therapeutics
FLNA
$48.2M
$5.28M 0.37%
85,000
-30,000
-26% -$2.5M
SAGE
75
DELISTED
Sage Therapeutics
SAGE
$5.1M 0.36%
115,000
+40,000
+53% +$1.83M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rhenman & Partners Asset Management held 97 positions worth $1.42B, down 3.3% from $1.47B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $49.9M of net new capital in Q3 2021, opening 3 new positions and adding to 35 existing holdings. Its largest new stake was Privia Health: 240,000 shares worth $5.65M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Acceleron Pharma, an estimated $25.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2021 buy was Privia Health: 240,000 shares worth $5.65M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q3 2021, an estimated $33.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.6M.
  • Rhenman & Partners Asset Management fully exited Inovalon Holdings, Inc. Class A Common Stock in Q3 2021, selling an estimated $20.4M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q3 2021.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 5 in Q3 2021.
  • Rhenman & Partners Asset Management's portfolio value fell 3.3% quarter-over-quarter to $1.42B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.